Demographics, Prior Therapies, and Reasons for Cemiplimab Treatment: Prospective CemiplimAb-Rwlc Survivorship and Epidemiology (C.A.S.E.) Study in Patients With Advanced Cutaneous Squamous Cell Carcinoma. J of Skin 2020, 4 (6), s125. https://doi.org/10.25251/skin.4.supp.125.